Layer, Chiang, et al. Genome Biology
Choosing Skin and Eye Disorders, RXi Will Face Well-Worn R&D Paths
The two areas, which have opportunities RXi's CEO called "tremendous" and "significant," have been well worn by rival drug companies making similar bets including Sirnaomics, TransDerm, and Quark Pharmaceuticals.
New to GenomeWeb? Register here quickly.